Suraksha Diagnostic Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Suraksha Diagnostic Ltd trades at ₹252, in a downtrend and 87 weeks into that stage. That is −10.3% against its own 200-day average. It sits at 20% of a 52-week range of ₹236 to ₹320. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (9 weeks and counting).

Today the stock is in a downtrend — week 87 of stage 4, confirmed. At ₹252 it trades −10.3% versus its 200-day average and sits at 20% of its 52-week range (₹236–₹320).

Against the market, two honest reads. Cumulative: over the last 1.7 years the stock moved −40% while the NIFTY 500 moved +0% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-17) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Suraksha Diagnostic Ltd trades at 40.8× P/E, near the bottom of its own range — cheaper only 33% of the time. Its long-run median P/E is 43.9×, measured across 1.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 40.8× is near the bottom of its own range — cheaper only 33% of the time, against a long-run median of 43.9× measured over 1.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +1.1% against a −16.2% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Suraksha Diagnostic Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

4-Factor Sector Score

39.0/100 — rank 8 of 9 in Diagnostics · 76% evidence confidence

Suraksha Diagnostic Ltd scores 39.0 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 13.8 + 13 + 10.4 + 1.8 = 39. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Suraksha Diagnostic Ltd reported ₹81.4 Cr of revenue in the Mar 26 quarter, +25.1% year on year. That is the 7th straight quarter of year-on-year growth. Over 6 years it has compounded at 11.9% a year. The last full year, FY26, came in at ₹310 Cr. The last four reported quarters add to ₹310 Cr.

FY26 revenue came in at ₹310 Cr (+23.0% on the year), capping 6 years at 11.9% compound. The latest quarter (Mar 26) printed ₹81.4 Cr, +25.1% year on year — the 7th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +23.3% growth against the decade's 11.9% — the current year is running faster than its own long-run rate.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Suraksha Diagnostic Ltd's operating margin is 29.9% in the Mar 26 quarter, +0.5 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 18.0% to 33.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 29.9%, +0.5 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 18.0%–33.0%.

Why the margin moved: operating margin went +0.5 pp year on year while gross margin went +1.1 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Suraksha Diagnostic Ltd earned ₹6.2 Cr of net profit in the Mar 26 quarter, −14.1% year on year. Full-year FY26 profit was ₹31.0 Cr. The 6-year compound rate is 12.9%. That is 7.6% of the quarter's revenue. The same quarter a year earlier earned ₹7.2 Cr.

Mar 26 profit was ₹6.2 Cr, −14.1% year on year. On the full year, FY26 printed ₹31.0 Cr (+0.0%), and the 6-year compound rate is 12.9%.

🚨 Why profit moved: revenue contributed +25.1% and the margin +0.5 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +3.4% vs revenue +23.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 241% of Suraksha Diagnostic Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹82.0 Cr of operating cash against ₹31.0 Cr of profit. After ₹158 Cr of capital spending, ₹−76.0 Cr was left as free cash.

FY26: operating cash of ₹82.0 Cr against reported profit of ₹31.0 Cr, leaving free cash of ₹−76.0 Cr after ₹158 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 241% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 241%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 2.4× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Suraksha Diagnostic Ltd's cash conversion cycle runs −101 days in FY26, down from −99 days in FY21. Capital spending ran ₹263 Cr over the last 3 years. At FY26 sales of ₹310 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹−86.0 Cr sits inside the business at any moment.

FY26: debtors at 27 days, inventory at 81 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −101 days, tighter than FY21's −99.

The full loop: cash goes out to suppliers and production on day 0; stock waits 81 days to sell; customers pay about 27 days after that; and suppliers themselves are paid at 209 days — netting out to the −101-day cycle.

In money terms: at FY26 sales of ₹310 Cr, each day of the cycle holds about ₹0.8 Cr — so the −101-day loop keeps roughly ₹−86.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹263 Cr over the last 3 fiscal years against ₹109 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹35.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Suraksha Diagnostic Ltd earns a ROCE of 17% in FY26. That is up from a trough of 8% in FY21. Return on invested capital clears the cost of that capital by −0.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 10.0% net margin on 0.69× asset turns.

FY26 ROCE is 17%, recovered from a FY21 trough of 8% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 10.0% net margin × 0.69× asset turns × 1.84× balance-sheet leverage ≈ 12.7% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 11.8% − 12.0% = a −0.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Suraksha Diagnostic Ltd carries total debt of ₹130 Cr against shareholder equity of ₹243 Cr as of Mar 26, a debt-to-equity of 0.53. On the annual view that ratio went from 0.50 in FY24 to 0.53 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹130 Cr against shareholder equity of ₹243 Cr — a debt-to-equity of 0.53. On the annual view, debt-to-equity went from 0.50 (FY24) to 0.53 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 2.8 points of Suraksha Diagnostic Ltd over 6 quarters, the biggest move on the register. That takes domestic institutions to 23.2% of the company. Foreign institutions moved −1.9 points over the same window, to 13.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +2.8 points over 6 quarters to 23.2%; Foreign institutions: −1.9 points over 6 quarters to 13.5%; Promoters: +0.3 points over 6 quarters to 49.1%.

Why the register moved: rotation — foreign institutions −1.9 points against domestic institutions +2.8 points over 6 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Suraksha Diagnostic Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions